NeurologyLive® Friday 5 — August 12, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Mind Moments^® Episode 70: Raising Awareness of Acute Flaccid Myelitis

Mind Moments^®, a podcast from NeurologyLive^®, brings you an exclusive interview with Olwen C. Murphy, MBBCh; and Matthew R. Vogt, MD, PhD, who spoke about the current clinical understanding of acute flaccid myelitis (AFM) and the existing treatment approach, as well as the current guidelines and the need to improve awareness ahead of the peak infection months in autumn.

2: Recognizing Lysosomal Autophagy as a Realistic Target for Alzheimer Disease: Ralph Nixon, MD, PhD

The professor of psychiatry and cell biology at NYU Langone pleaded his case for why the Alzheimer community should begin to turn to other drug development strategies, including the relatively young phenomenon of autophagy.

3: NeuroVoices: Vesna Garovic, MD, PhD, on Severe Preclampsia’s Effect on Late-Life Cognition, Neuroinflammation for Women

In the latest edition of our Q&A series, the chair of the nephrology division at Mayo Clinic provided context on new findings on the risks of preeclampsia, a hypertensive disorder, and elevated levels of neuroinflammation and neurovascular damage.

4: Ever-Changing Face of MS: Evolution and Prevalence of Multiple Sclerosis

Ahmed Obeidat, MD, PhD; and Randall Schapiro, MD, FAAN, discuss the prevalence of multiple sclerosis and highlight how the disease has evolved since they began practicing. They also review the impact it has on patients and their support communities.

5: The Wide-Reaching Impact of Multiple Sclerosis DMT Wastes: Darin T. Okuda, MD; Karin Cook

The professor of neurology and director of Neuroinnovation and the Multiple Sclerosis & Neuroimmunology Imaging Program at The University of Texas Southwestern Medical Center at Dallas; and senior vice president of medical strategy and clinical ethnographer at Heartbeat Medical Communications discussed the costs associated with unused disease-modifying therapies in MS.

—————————————————